Disclosed herein are methods of cellular reprogramming, comprising contacting a cell with HC-HA/PTX3 for a time sufficient for cellular reprogramming of the phenotype of the cell to a different phenotype.

Dietary supplements and formulations for a subject, including veterinary animals and humans, in an oral preparation and/or parenteral preparation, are provided. The formulations comprise elevated amounts of hydrolyzed collagen, a glucosamine salt, a glycosaminoglycan, a sulfone, a polysaccharide acid, an ascorbate salt, a transition metal, and a polyunsaturated fatty acid. A method for enhancing joint health and/or joint repair in a subject, including veterinary animals and humans, having a joint disorder or a disease associated therewith, is also provided, comprising administering the preparation comprising high amounts of hydrolyzed collagen.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

Pharmaceutical compositions comprising a tyrosine kinase inhibitor and a farnesyltransferase inhibitor, or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier, as well as methods for preventing or treating cancer by administering the same are disclosed herein.

The present disclosure pertains to compositions with reduced presence of host-cell proteins and methods of making such compositions. In particular, it pertains to compositions methods of making compositions with reduced presence of host-cell proteins from a host-cell.

The present disclosure provides methods of treating cancer in a patient determined to have osimertinib resistant EGFR mutations by administering a second-generation quinazolinamine derivative tyrosine kinase inhibitor.

The disclosure provides for peptide-functionalized biodegradable polymers, and methods of using the polymers for efficiently delivering RNAs of various sizes, and secondary structures inside cells.

A composition comprising a combination of N-Phenylacetyl-L-prolylglycine ethyl ester and cannabidiol for oral administration to humans and other animals and a method for administering said composition are described. The composition provides synergistic nootropic benefits to the user, resulting in enhanced cognitive functions, such as increased focus, creativity, memory recall, and memory consolidation, among other cognitive functions. The composition generally does not cause side effects in the users and generally does not cause the user to develop tolerance to its nootropic effects. The composition optionally comprises a compound containing choline or a choline prodrug to supply choline to the brain of the user for the production of the neurotransmitter acetylcholine, and may also optionally comprise caffeine.

In alternative embodiments, provided are pharmaceutical compositions and methods for treating, ameliorating, reversing and/or preventing (acting as a prophylaxis) autism, e.g., regressive autism. In alternative embodiments, these pharmaceutical compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, pharmaceutical compositions and methods are dosaged, formulated and dosaged as solid, liquid or aerosol preparations or formulations. In alternative embodiments, pharmaceutical compositions comprise rifaximin as the sole antibiotic, or rifaximin and other antimicrobial or antibiotic agent, for example, vancomycin, metronidazole, tinidazole or a combination thereof.

The present invention relates to methods for producing a stable amorphous dispersion of a pharmaceutically active substance having poor water solubility by applying low frequency acoustic energy to a mixture comprising the active substance and at least one polymer and heating the mixture until a stable amorphous dispersion is formed. The methods of the invention are an effective means of converting a crystalline API to a substantially amorphous and stable form, i.e., wherein the crystallinity is less than about 5%. The methods of the invention result in more complete amorphization, increased solubility, drug loading and stability as compared typical amorphization or literature methods.